GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anterogen Co Ltd (XKRX:065660) » Definitions » Additional Paid-In Capital

Anterogen Co (XKRX:065660) Additional Paid-In Capital : ₩98,674 Mil(As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Anterogen Co Additional Paid-In Capital?


Anterogen Co's quarterly additional paid-in capital stayed the same from Sep. 2023 (₩98,674 Mil) to Dec. 2023 (₩98,674 Mil) and stayed the same from Dec. 2023 (₩98,674 Mil) to Mar. 2024 (₩98,674 Mil).

Anterogen Co's annual additional paid-in capital increased from Dec. 2021 (₩91,709 Mil) to Dec. 2022 (₩98,856 Mil) but then declined from Dec. 2022 (₩98,856 Mil) to Dec. 2023 (₩98,674 Mil).


Anterogen Co Additional Paid-In Capital Historical Data

The historical data trend for Anterogen Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anterogen Co Additional Paid-In Capital Chart

Anterogen Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 84,682.58 95,811.77 91,708.89 98,855.77 98,674.39

Anterogen Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95,885.37 98,674.39 98,674.39 98,674.39 98,674.39

Anterogen Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Anterogen Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Anterogen Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Anterogen Co (XKRX:065660) Business Description

Traded in Other Exchanges
N/A
Address
Namsung Plaza, Gasan-dong, 405, 130, Digital-ro, Geumcheon-gu, Seoul, KOR, 08589
Anterogen Co Ltd is a bio-venture company engaged in the research and development of cell therapy products and orphan drugs using adult stem cells. Its products include Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. The company also offers cell banking services and analysis services that include sample analysis for clinical studies.

Anterogen Co (XKRX:065660) Headlines

No Headlines